Amyloid-β, p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease

被引:15
|
作者
Frigerio, Irene [1 ]
Boon, Baayla D. C. [2 ]
Lin, Chen-Pei [1 ]
Galis-de Graaf, Yvon [1 ]
Bol, John [1 ]
Preziosa, Paolo [3 ,4 ]
Twisk, Jos [5 ]
Barkhof, Frederik [6 ,7 ]
Hoozemans, Jeroen J. M. [2 ]
Bouwman, Femke H. [8 ]
Rozemuller, Annemieke J. M. [2 ]
van de Berg, Wilma D. J. [1 ]
Jonkman, Laura E. [1 ]
机构
[1] Vrije Univ Amsterdam, Dept Anat & Neurosci, Amsterdam UMC, Locat VUmc,Amsterdam Neurosci,Sect Clin Neuroanat, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam UMC, Locat VUmc, Amsterdam Neurosci, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] IRCCS San Raffaele Sci Inst, Neuroimaging Res Unit, Div Neurosci, I-20132 Milan, Italy
[4] IRCCS San Raffaele Sci Inst, Neurol Unit, I-20132 Milan, Italy
[5] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, NL-1081 HV Amsterdam, Netherlands
[6] Amsterdam UMC, Amsterdam Neurosci, Dept Radiol & Nucl Med, Locat VUmc, NL-1081 HV Amsterdam, Netherlands
[7] UCL, Inst Neurol & Healthcare Engn, London WC1E, England
[8] Alzheimer Ctr Amsterdam, Amsterdam Neurosci, Amsterdam UMC, Alzheimer Centrum Amsterdam,Locat VUmc,Dept Neuro, NL-1081 HV Amsterdam, Netherlands
关键词
Alzheimer's disease; cortical thickness; neuropathology; MRI; atypical Alzheimer's disease; NEUROPATHOLOGIC ASSESSMENT; DEFINED SUBTYPES; PET PATTERNS; IN-VIVO; BRAIN; GRAY; INFLAMMATION; ASSOCIATION;
D O I
10.1093/braincomms/fcab281
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Frigerio et al. report that in Alzheimer's disease, amyloid-beta, phosphorylated-tau and reactive microglia load measured with immunohistochemistry, are important correlates of MRI cortical atrophy, acquired both ante-mortem in vivo and post-mortem in situ. In summary, distinct histopathological markers differently correlate with cortical atrophy, highlighting their different roles in the neurodegeneration process. Alzheimer's disease is characterized by cortical atrophy on MRI and abnormal depositions of amyloid-beta, phosphorylated-tau and inflammation pathologically. However, the relative contribution of these pathological hallmarks to cortical atrophy, a widely used MRI biomarker in Alzheimer's disease, is yet to be defined. Therefore, the aim of this study was to identify the histopathological correlates of MRI cortical atrophy in Alzheimer's disease donors, and its typical amnestic and atypical non-amnestic phenotypes. Nineteen Alzheimer's disease (of which 10 typical and 9 atypical) and 10 non-neurological control brain donors underwent post-mortem in situ 3T 3D-T1, from which cortical thickness was calculated with Freesurfer. Upon subsequent autopsy, 12 cortical brain regions from the right hemisphere and 9 from the left hemisphere were dissected and immunostained for amyloid-beta, phosphorylated-tau and reactive microglia, and percentage area load was calculated for each marker using ImageJ. In addition, post-mortem MRI was compared to ante-mortem MRI of the same Alzheimer's disease donors when available. MRI-pathology associations were assessed using linear mixed models. Higher amyloid-beta load weakly correlated with higher cortical thickness globally (r = 0.22, P = 0.022). Phosphorylated-tau strongly correlated with cortical atrophy in temporal and frontal regions (-0.76 < r < -1.00, all P < 0.05). Reactive microglia load strongly correlated with cortical atrophy in the parietal region (r = -0.94, P < 0.001). Moreover, post-mortem MRI scans showed high concordance with ante-mortem scans acquired <1 year before death. In conclusion, distinct histopathological markers differently correlated with cortical atrophy, highlighting their different roles in the neurodegenerative process, and therefore contributing to the understanding of the pathological underpinnings of MRI atrophic patterns in Alzheimer's disease. In our cohort, no or only subtle differences were found in MRI-pathology associations in Alzheimer's disease phenotypes, indicating that the histopathological correlates of cortical atrophy in typical and atypical phenotypes might be similar. Moreover, we show that post-mortem in situ MRI can be used as proxy for ante-mortem in vivo MRI.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
    Therriault, Joseph
    Pascoal, Tharick A.
    Savard, Melissa
    Benedet, Andrea L.
    Chamoun, Mira
    Tissot, Cecile
    Lussier, Firoza
    Kang, Min Su
    Thomas, Emilie
    Terada, Tatsuhiro
    Rej, Soham
    Massarweh, Gassan
    Nasreddine, Ziad
    Vitali, Paolo
    Soucy, Jean-Paul
    Saha-Chaudhuri, Paramita
    Gauthier, Serge
    Rosa-Neto, Pedro
    NEUROLOGY, 2021, 96 (01) : E81 - E92
  • [22] CSF p-Tau levels in the prediction of Alzheimer's disease
    Kandimalla, Ramesh J. L.
    Prabhakar, Sudesh
    Wani, Willayat Yousuf
    Kaushal, Alka
    Gupta, Nidhi
    Sharma, Deep Raj
    Grover, V. K.
    Bhardwaj, Neerja
    Jain, Kajal
    Gill, Kiran Dip
    BIOLOGY OPEN, 2013, 2 (11): : 1119 - 1124
  • [23] Morphometric Similarity Patterning of Amyloid-β and Tau Proteins Correlates with Transcriptomics in the Alzheimer's Disease Continuum
    Brusini, Lorenza
    Dolci, Giorgio
    Pini, Lorenzo
    Cruciani, Federica
    Pizzagalli, Fabrizio
    Provero, Paolo
    Menegaz, Gloria
    Galazzo, Ilaria Boscolo
    Alzheimers Dis Neuroimaging Initiative
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [24] Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
    Fossati, Silvia
    Ramos Cejudo, Jaime
    Debure, Ludovic
    Pirraglia, Elizabeth
    Sone, Je Yeong
    Li, Yi
    Chen, Jingyun
    Butler, Tracy
    Zetterberg, Henrik
    Blennow, Kaj
    de Leon, Mony J.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2019, 11 (01) : 483 - 492
  • [25] CSF P-tau 231 as Biomarker in Alzheimer's Disease
    Mukherjee, Adreesh
    Biswas, Atanu
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2022, 25 (06) : 995 - 996
  • [26] Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays
    van Harten, Argonde C.
    Wiste, Heather J.
    Weigand, Stephen D.
    Mielke, Michelle M.
    Kremers, Walter K.
    Eichenlaub, Udo
    Dyer, Roy B.
    Algeciras-Schimnich, Alicia
    Knopman, David S.
    Jack Jr, Clifford R.
    Petersen, Ronald C.
    ALZHEIMERS & DEMENTIA, 2022, 18 (04) : 635 - 644
  • [27] Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease
    Moosavi, Behrooz
    Mousavi, Bibimaryam
    Macreadie, Ian G.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (01) : 9 - 16
  • [28] Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer’s disease
    Daniel Saiz-Sanchez
    Carlos De la Rosa-Prieto
    Isabel Ubeda-Banon
    Alino Martinez-Marcos
    Brain Structure and Function, 2015, 220 : 2011 - 2025
  • [29] Interneurons, tau and amyloid-β in the piriform cortex in Alzheimer's disease
    Saiz-Sanchez, Daniel
    De la Rosa-Prieto, Carlos
    Ubeda-Banon, Isabel
    Martinez-Marcos, Alino
    BRAIN STRUCTURE & FUNCTION, 2015, 220 (04): : 2011 - 2025
  • [30] Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade
    Gulisano, Walter
    Maugeri, Daniele
    Baltrons, Marian A.
    Fa, Mauro
    Amato, Arianna
    Palmeri, Agostino
    D'Adamio, Luciano
    Grassi, Claudio
    Devanand, D. P.
    Honig, Lawrence S.
    Puzzo, Daniela
    Arancio, Ottavio
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S611 - S631